Our results demonstrated that the IDO+SIs in breast cancer PTs were significantly higher in tumors of more advanced stages and with more extensive lymph node metastasis, which correlated with a comparably worse clinical outcome. This evidence concerns the gene IDO1 and breast carcinoma.